New York State Common Retirement Fund cut its position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 10.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,104 shares of the medical research company’s stock after selling 10,500 shares during the period. New York State Common Retirement Fund’s holdings in PRA Health Sciences were worth $9,444,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRAH. State of Michigan Retirement System raised its holdings in shares of PRA Health Sciences by 32.6% during the 2nd quarter. State of Michigan Retirement System now owns 23,197 shares of the medical research company’s stock worth $2,257,000 after acquiring an additional 5,697 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its position in PRA Health Sciences by 38.2% in the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 3,259 shares of the medical research company’s stock worth $317,000 after purchasing an additional 900 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in PRA Health Sciences during the third quarter valued at $4,107,000. TD Asset Management Inc. lifted its position in PRA Health Sciences by 7.9% during the second quarter. TD Asset Management Inc. now owns 190,900 shares of the medical research company’s stock valued at $18,573,000 after purchasing an additional 13,900 shares during the last quarter. Finally, Strs Ohio grew its stake in shares of PRA Health Sciences by 101.5% in the 2nd quarter. Strs Ohio now owns 15,828 shares of the medical research company’s stock worth $1,539,000 after buying an additional 7,974 shares in the last quarter. Institutional investors and hedge funds own 96.69% of the company’s stock.

PRAH has been the subject of a number of analyst reports. Bank of America downgraded shares of PRA Health Sciences from a “buy” rating to an “underperform” rating and lowered their price target for the company from $110.00 to $100.00 in a report on Monday, August 10th. Mizuho lifted their target price on PRA Health Sciences from $92.00 to $108.00 and gave the stock an “in-line” rating in a report on Monday, August 10th. UBS Group increased their price target on PRA Health Sciences from $105.00 to $111.00 and gave the company a “neutral” rating in a report on Monday, August 10th. BidaskClub downgraded PRA Health Sciences from a “hold” rating to a “sell” rating in a research report on Monday, November 2nd. Finally, Citigroup lifted their price objective on shares of PRA Health Sciences from $90.00 to $110.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $106.42.

Shares of PRAH opened at $112.24 on Friday. The firm has a fifty day moving average price of $108.07 and a 200-day moving average price of $101.91. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $7.20 billion, a P/E ratio of 34.43, a P/E/G ratio of 3.82 and a beta of 1.05. PRA Health Sciences, Inc. has a 12-month low of $58.67 and a 12-month high of $118.44.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.16. The company had revenue of $796.31 million during the quarter, compared to analysts’ expectations of $769.14 million. PRA Health Sciences had a net margin of 6.86% and a return on equity of 25.01%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.32 EPS. Analysts predict that PRA Health Sciences, Inc. will post 3.71 earnings per share for the current year.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: What is Forex?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.